Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at Syneos Health and at advertising agency WPP. According to the company, Loreaux has resigned as CEO due to family matters but will continue as a member of the board of directors.
In 2019, Bryn announced that it had acquired a license to use Aptar Pharma’s Bidose nasal pump for delivery of NDS1C for the treatment of anaphylaxis. In February 2023, Bryn presented dats showing that a 13.2 mg dose of NDS1C epinephrine nasal spray (Utuly) was absorbed as fast as a 0.3 mg dose from an autoinjector while producing higher and longer-lasting epinephrine plasma levels.
Ziel commented, “I am excited to join Bryn Pharma as we finalize the regulatory pathway and commercial strategy for NDS1C. There is an incredible potential with NDS1C to bring patients best-in-class, needle-free epinephrine administration for anaphylaxis that is comparable to the EpiPen, and I look forward to working with Sandy to build on the momentum established by the impressive team at Bryn Pharma.”
Board Chairman Steven Hartman said, “I am confident in Josh’s expertise and leadership, and I look forward to working closely with him as we continue to advance NDS1C toward regulatory approval. We have a significant opportunity to differentiate our product in the large and growing epinephrine market and Bryn Pharma is well positioned to deliver on the profound unmet need in this space.”
Read the Bryn Pharma press release.
